The Galleri Test: What you should know
Cancer screening is one of the most important parts of preventive medicine.
The goal is simple: find cancer early, when treatment is more likely to work.
Traditional screening tests are designed for specific cancers. Examples include colonoscopy for colorectal cancer, mammography for breast cancer, Pap smears and HPV testing for cervical cancer, low-dose CT scans for lung cancer in high-risk patients, and PSA testing in select men after shared decision-making.
The Galleri test takes a different approach.
It is a blood test designed to look for a cancer signal across many different cancer types at once.
That idea is appealing, especially in a personalized longevity or executive health setting. Many deadly cancers do not have standard screening tests, and a single blood draw that could detect multiple cancers earlier sounds like a major advance.
But the test also has important limitations.
My view is that the Galleri test may have a role in highly personalized care for selected patients who understand the tradeoffs. But it is not something I would recommend routinely for the entire general population at this time.
What is the Galleri test?
The Galleri test is a blood-based multi-cancer early detection test, often called an MCED test.
It was developed by GRAIL and is designed to detect a shared cancer signal from cell-free DNA in the blood.
Cells in the body release small fragments of DNA into the bloodstream. Cancer cells can release DNA as well. The Galleri test analyzes methylation patterns on this cell-free DNA and uses machine learning to look for patterns associated with cancer.
If a cancer signal is detected, the test also attempts to predict the likely cancer signal origin, meaning the tissue or organ where the cancer may be coming from.
That information is meant to help guide the diagnostic workup.
This is different from a standard blood test that measures one tumor marker.
The Galleri test is looking for a broader cancer-associated signal across more than 50 cancer types.
What the test is trying to solve
Many cancers do not have widely recommended screening tests.
We have established screening for cancers such as:
Breast cancer
Colorectal cancer
Cervical cancer
Lung cancer in high-risk patients
Prostate cancer in selected men after discussion
But many cancers are still often found only after symptoms develop.
Examples include:
Pancreatic cancer
Ovarian cancer
Liver cancer
Esophageal cancer
Stomach cancer
Some blood cancers
Some head and neck cancers
These cancers can be difficult to detect early.
That is the appeal of a multi-cancer blood test.
If a blood test could safely detect aggressive cancers earlier, it could potentially improve outcomes.
But that last sentence contains the key word:
Potentially.
Detecting a signal earlier is not the same as proving that people live longer because of the test.
The potential benefits
The Galleri test has several appealing features.
First, it is a blood test. That makes it easier for many patients than procedures such as colonoscopy or imaging studies.
Second, it looks across many cancer types, including some cancers that do not currently have standard screening options.
Third, its reported specificity is high, meaning the false-positive rate appears relatively low compared with what one might expect from a broad cancer screening test.
Fourth, when the test is truly positive, it may often predict the likely cancer signal origin, which can help guide follow-up testing.
In a personalized medicine setting, these features make the test attractive.
For a patient who understands the limitations, accepts the possibility of additional workup, and wants a more comprehensive screening approach, Galleri may be reasonable to discuss.
Test performance: specificity is strong
One of the test’s strengths is its high specificity.
In validation data, Galleri had a reported specificity of approximately 99.5%.
That means most people without cancer will have a negative result.
This matters because a multi-cancer screening test with poor specificity could create enormous harm through false positives, anxiety, unnecessary imaging, biopsies, procedures, and cost.
A high-specificity test is important if the goal is to screen large numbers of people.
But specificity is only one part of the story.
The other major issue is sensitivity.
The key limitation: early-stage sensitivity
The main limitation of the Galleri test is that sensitivity is highly stage-dependent.
In the major clinical validation data, overall sensitivity was reported around 51.5%.
But sensitivity was much lower for early-stage cancer:
Stage I: about 16.8%
Stage II: about 40.4%
Stage III: about 77.0%
Stage IV: about 90.1%
This is the central concern.
The purpose of screening is not just to find cancer.
The purpose is to find cancer early enough to change outcomes.
A test that performs better in later-stage disease may detect cancers that are already more advanced. That may still be useful in some cases, but the greatest screening value usually comes from finding cancer before it has spread or caused symptoms.
So while the test is scientifically impressive, its limited sensitivity for stage I disease is a major reason it should not be oversold.
Positive results require real diagnostic workup
A positive Galleri test does not diagnose cancer.
It detects a cancer signal.
That signal then requires follow-up evaluation, which may include:
Physician visit
Repeat history and physical exam
Targeted labs
CT, MRI, PET/CT, ultrasound, or other imaging
Endoscopy or colonoscopy
Specialist referral
Biopsy if a suspicious lesion is found
This can be appropriate and potentially helpful.
But it can also create anxiety, cost, radiation exposure, incidental findings, and invasive testing.
In the PATHFINDER study, a small percentage of participants had a positive cancer signal. Among those positives, some were true positives and some were false positives.
False positives matter because patients can spend weeks or months undergoing workup without ultimately finding cancer.
That does not mean the test should never be used.
It means the patient needs to understand what a positive result could lead to before ordering the test.
Negative results can also be misleading
A negative Galleri test does not mean a person is cancer-free.
This is very important.
Because sensitivity is limited, especially for early-stage cancers, a negative result can miss cancer.
The concern is false reassurance.
A patient might think:
“My Galleri test was negative, so I do not need colonoscopy.”
That would be the wrong conclusion.
Galleri is intended to complement standard screening, not replace it.
A negative Galleri result should not be used as a reason to skip:
Colonoscopy or stool-based colon cancer screening
Mammography
Pap smear or HPV testing
Lung cancer screening when indicated
Skin checks for high-risk patients
PSA discussion when appropriate
The most proven cancer screening tools remain the foundation.
Galleri is not FDA-approved
The Galleri test is currently available in the United States as a laboratory-developed test.
That is different from being FDA-approved as a routine population screening test.
This distinction matters.
It means the test can be ordered clinically, but the evidence base is still evolving.
It also means coverage may be limited, and patients often pay out of pocket.
For some patients, that cost may be acceptable. For others, it may not be the best use of preventive health dollars.
The unresolved question: does it save lives?
This is the most important question.
A cancer screening test should ultimately reduce cancer mortality or improve meaningful clinical outcomes.
For Galleri and other MCED tests, that has not yet been definitively proven.
Much of the optimism is based on the hope that earlier detection will create a stage shift — finding more cancers at earlier stages and fewer at later stages.
That makes sense.
But stage shift is a surrogate outcome.
The real endpoint is whether testing leads to fewer cancer deaths, less suffering, better quality of life, or more effective treatment.
At this time, we do not yet have definitive randomized trial evidence showing that Galleri reduces cancer mortality in the general population.
That is why I view the test as promising but not yet routine.
The NHS-Galleri trial issue
The NHS-Galleri trial was one of the largest studies designed to evaluate this type of testing in a screening population.
The trial used reduction in late-stage cancers as a key endpoint rather than cancer mortality.
Based on available reporting, the study did not meet its primary endpoint at the end of the study, although the sponsor emphasized a shift from stage IV to stage III diagnoses.
That distinction matters.
A shift from stage IV to stage III may be biologically and clinically interesting.
But it is not the same as proving fewer people died from cancer.
For a test to become standard routine screening, we need to know that benefits outweigh harms at the population level.
Overdiagnosis is another concern
Another unresolved issue is overdiagnosis.
Overdiagnosis means detecting a cancer or cancer-like abnormality that would never have caused symptoms or death during a person’s lifetime.
This is a known issue in cancer screening.
The challenge with multi-cancer early detection testing is that we do not yet fully know how often it may lead to overdiagnosis.
Some detected cancers may be aggressive and important to find.
Others may be slow-growing, clinically uncertain, or discovered incidentally during follow-up.
Overdiagnosis can lead to unnecessary procedures, treatment, anxiety, complications, and cost.
This risk is not unique to Galleri.
But it is important when discussing any screening test.
False positives and downstream testing
Even with high specificity, false positives will happen.
When testing large numbers of healthy people, even a small false-positive rate can lead to many follow-up evaluations.
A false-positive result can trigger:
Repeat visits
Advanced imaging
Incidental findings
Specialist referrals
Biopsies
Months of uncertainty
Financial cost
Emotional distress
In highly personalized care, this may be manageable because the physician and patient can plan the workup carefully.
But for broad routine screening of the general population, the downstream burden becomes a major public health question.
Who manages the workup?
Who pays for the imaging?
What happens when imaging is negative?
How long should the patient be followed?
These are not small issues.
Where Galleri may fit
I do think there may be a role for Galleri in selected patients.
The test may be reasonable to discuss in people who:
Are older adults interested in advanced screening
Understand that the test is not FDA-approved
Understand that no mortality benefit has been proven
Are already up to date on standard cancer screening
Have access to thoughtful follow-up care
Can tolerate uncertainty and possible false positives
Are willing to pursue diagnostic testing if positive
Can afford the test without sacrificing higher-value care
Want a more personalized, proactive screening discussion
In that context, Galleri may fit into a high-touch preventive care model.
But it should be used with informed consent, not as a blanket recommendation.
Where Galleri does not fit
I would be more cautious using Galleri when:
A patient is not up to date on proven screening
The test would replace colonoscopy, mammography, Pap/HPV testing, or lung screening
The patient is unlikely to complete follow-up testing
The patient has severe anxiety around uncertain results
Cost is a major burden
There is no clear plan for a positive result
The patient assumes a negative result means “no cancer”
The test is being marketed as a definitive full-body cancer screen
The biggest mistake would be using Galleri instead of proven screening.
The test should be additive, not substitutive.
Galleri vs. traditional screening
Traditional screening tests have stronger outcome data for specific cancers.
For example:
Colonoscopy can detect and remove precancerous polyps.
Mammography can detect breast cancer earlier in appropriate age groups.
Pap and HPV testing can prevent cervical cancer by detecting precancerous changes.
Low-dose CT can reduce lung cancer mortality in appropriately selected high-risk individuals.
These tests are imperfect, but they are guideline-supported and have a clearer evidence base.
Galleri is different.
It may detect cancers that lack routine screening options, but it does not yet have the same level of outcome evidence.
So the hierarchy should be:
First: complete guideline-recommended screening.
Then: consider Galleri as an optional additional tool in selected patients.
My practical approach
If a patient asks about Galleri, I would frame the discussion around four questions.
1. Are you up to date on standard screening?
If not, that comes first.
2. Do you understand what the test can and cannot do?
A negative result does not rule out cancer. A positive result does not diagnose cancer.
3. Are you prepared for follow-up testing if the result is positive?
This may include imaging, procedures, specialist visits, and waiting.
4. Does this fit your values and risk tolerance?
Some patients want more information even with uncertainty. Others prefer to avoid testing that lacks proven mortality benefit.
This should be a shared decision, not a sales pitch.
The role in longevity medicine
In longevity medicine, patients often want to detect disease before symptoms appear.
That is reasonable.
But advanced screening should be held to a high standard.
More testing is not automatically better.
A good longevity strategy should distinguish between:
High-value screening
Reasonable optional testing
Experimental testing
Low-value testing
Testing that may create more harm than benefit
Galleri fits best in the “reasonable optional testing” category for selected patients, not the “routine for everyone” category.
It may have a role when integrated into a thoughtful prevention plan that includes standard screening, risk assessment, lifestyle, family history, and physician-guided follow-up.
What I tell patients
My position is balanced:
I do not think Galleri should be marketed as a routine cancer screening test for everyone.
But I also do not dismiss it completely.
For selected patients in a personalized care setting, it may be worth discussing as an additional layer of screening, especially for cancers without standard screening tools.
However, patients must understand that the test has limitations:
It is not FDA-approved
It can miss cancer
It is less sensitive for early-stage disease
It can produce false positives
It may lead to costly or invasive workups
It has not been proven to reduce cancer mortality
It does not replace standard cancer screening
That is the responsible way to use it.
Bottom line
The Galleri test is a blood-based multi-cancer early detection test that analyzes cell-free DNA methylation patterns to look for a cancer signal across more than 50 cancer types.
It is one of the most promising developments in cancer screening, especially because many deadly cancers currently lack standard screening tests.
But the test is not perfect.
Its specificity is high, but sensitivity is limited, especially for early-stage disease. A negative result does not rule out cancer, and a positive result requires diagnostic follow-up.
Most importantly, Galleri has not yet been proven to reduce cancer mortality in the general population.
For now, I view Galleri as an optional tool for selected patients who are already up to date on standard screening and who understand the risks, costs, and uncertainty.
It may have a role in highly personalized preventive care.
But it should complement — not replace — proven cancer screening.